920 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Downtrend
Article Searches
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million http://www.zacks.com/stock/news/360866/novartis-nvs-alcon-acquired-powervision-for-%24285-million?cid=CS-ZC-FT-360866 Mar 18, 2019 - Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy http://www.zacks.com/stock/news/358436/gilead-reports-positive-data-on-hiv-drugs-biktarvy-descovy?cid=CS-ZC-FT-358436 Mar 08, 2019 - Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Top Research Reports for Microsoft, Mastercard & General Electric http://www.zacks.com/research-daily/228770/top-research-reports-for-microsoft-mastercard-general-electric?cid=CS-ZC-FT-228770 Mar 08, 2019 - Top Research Reports for Microsoft, Mastercard & General Electric
Stocks making the biggest moves premarket: Big Lots, Navistar, Tilray & more https://www.cnbc.com/2019/03/08/stocks-making-the-biggest-moves-premarket-big-lots-navistar-tilray--more.html Mar 08, 2019 - Names on the move ahead of the open.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy http://www.zacks.com/stock/news/358194/gilead-reports-positive-data-on-hiv-drugs-biktarvy-descovy?cid=CS-ZC-FT-358194 Mar 07, 2019 - Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA http://www.zacks.com/stock/news/357971/roches-rhhby-snda-for-flu-candidate-accepted-by-the-fda?cid=CS-ZC-FT-357971 Mar 06, 2019 - The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.
Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda http://www.zacks.com/stock/news/357700/merck-gets-chmp-nod-for-six-week-dosing-option-of-keytruda?cid=CS-ZC-FT-357700 Mar 05, 2019 - Merck (MRK) gets CHMP recommendation for a six-week dosing schedule of Keytruda across all current monotherapy indications.
Stryker Acquires Arrinex For Rhinitis Treatment Tech https://seekingalpha.com/article/4246275-stryker-acquires-arrinex-rhinitis-treatment-tech?source=feed_sector_healthcare Mar 04, 2019 - Stryker announced that it has acquired Arrinex for an undisclosed sum.Arrinex has developed an FDA-approved cryoablation device to treat chronic adult rhinitis.SYK continues to acquire firms and techn
Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4 http://www.zacks.com/stock/news/357189/mallinckrodt-mnk-rallies-as-earnings-beat-estimates-in-q4?cid=CS-ZC-FT-357189 Feb 27, 2019 - Mallinckrodt (MNK) tops earnings and sales estimates in the fourth quarter leading to a gain in share price.
Tough Times Ahead for Mylan http://www.gurufocus.com/news/824205/tough-times-ahead-for-mylan Feb 27, 2019 - Tough Times Ahead for Mylan, Stocks: MYL,TEVA,GSK, release date:Feb 27, 2019

Pages: 123456...92

Page 1>

Related Companies

Name Exchange Price Mkt Cap
AZN Astrazeneca PLC NYSE $37.56 $95.16B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
SNY Sanofi NYSE $43.75 $109.14B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for GlaxoSmithKline PLC
GSK - Google Finance https://www.google.com/finance?q=GSK Industry related info and international coverage Summary News
GSK - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=GSK Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options